DeborahKArmstrongMD

Professor of Oncology, Professor of Gynecology and Obstetrics, Johns Hopkins University School of Medicine; Director, Breast and Ovarian Surveillance Service

Join to view full profile

Dr. Armstrong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Armstrong's full profile

Already have an account?

Office
10803 Falls Road
Pavilion Iii Ste 1500
Lutherville, MD 21093
Phone+1 410-583-2970

Fax+1 410-583-2980

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1989 - 1991
UPMC Medical EducationResidency, Internal Medicine, 1984 - 1987
George Washington University School of Medicine and Health SciencesClass of 1984

Certifications & Licensure

MD State Medical License 1988 - 2026
VA State Medical License 2022 - 2026
PA State Medical License 1986 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Start of enrollment: 1994 Oct 21
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Start of enrollment: 1998 Mar 01
Completed
Phase 3
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
Active, not recruiting
Phase 1, Phase 2
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
Stéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, William A Cliby, Mitchell I Edelson
Journal of Clinical Oncology. 2025-01-22
1 citations
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
Tullia Rushton, Harris B Krause, Timothy Samec, Andrew Elliott, Anthony N Karnezis
Gynecologic Oncology. 2024-12-01
2 citations
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham
Journal of the National Comprehensive Cancer Network. 2024-10-01

Lectures

A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

FDA Panel Backs Cryoablation in Early Breast Cancer as Alternative to SurgeryNovember 8th, 2024
Advisers to the FDA Back First Over-the-Counter Birth Control PillMay 10th, 2023
Hyperthermic Intraperitoneal Chemotherapy May Benefit Some Women with Ovarian CancerMarch 10th, 2022
Join now to see all

Committees

External Advisory Board Member, Fred Hutchinson Cancer Research Center, University off Washington 2017 - Present
Scientific Advisory Committee Member, Ovarian Cancer Research Alliance 2016 - Present
Ovarian cancer contributor, UpToDate 2014 - Present
External Advisory Committee Member, Mayo Clinic Ovarian Cancer SPORE 2014 - Present
Advisory Committee Member, The Marsha Rivkin Center for Ovarian Cancer Research 2008 - Present
Member, chair 2017-2020, Department of Defense, Congressionally Directed Medical Research Program, Ovarian Cancer Research Program 2007 - Present
Medical and Scientific Advisory Board, National Ovarian Cancer Coalition 2006 - Present
co-Chair 2018-2020, NIH Ovarian Task Force, Gynecologic Cancer Steering Committee 2014 - 2020
Chair, 2014-2016, Oncology Drugs Advisory Committee, FDA 2011 - 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
Society of Gynecologic Oncology
Member
American Association for Cancer Research - AACR
Member

Industry Relationships

Independent Data Monitoring Committee Member, DUO-E Trial, AstraZeneca2020 - Present
Independent Data Monitoring Committee Member and Chair, DUO-O Trial, AstraZeneca2018 - Present